HBM Partners

HBM Partners, established in 2001 and headquartered in Zug, Switzerland, stands as a prominent global investment firm exclusively dedicated to the healthcare sector. The firm's mandate is to invest in both private and public emerging biopharma and other healthcare-related companies, encompassing a broad spectrum from biotechnology and medical technology to diagnostics and digital health. With a deep-rooted expertise in life sciences, HBM Partners leverages a team comprising professionals with extensive scientific, medical, and financial backgrounds to identify and support innovative companies poised for significant growth.

The firm's investment strategy spans various stages, though it primarily focuses on growth-stage and late-stage private companies, alongside strategic investments in public equities. HBM Partners manages a substantial portfolio, with assets under management exceeding $1.6 billion, demonstrating its significant capacity to deploy capital across its target sectors. Their approach often involves taking significant minority stakes in their portfolio companies, providing not just capital but also strategic guidance and access to their extensive industry network. Since its inception, HBM Partners has invested in over 100 companies, showcasing a robust and diversified investment history within the healthcare landscape.

For private company investments, HBM Partners typically deploys initial checks ranging from $10 million to $50 million per company, reflecting their commitment to substantial, impactful investments in capital-intensive healthcare ventures. This range positions them as a key partner for companies seeking significant funding for clinical development, commercialization, or strategic expansion. HBM Partners is known for its long-term investment horizon, aiming to support its portfolio companies through various development milestones and market cycles, ultimately contributing to the advancement of healthcare innovation globally.